CN1219753C
(zh)
*
|
2000-07-19 |
2005-09-21 |
沃尼尔·朗伯公司 |
4-碘苯氨基苯氧肟酸的氧合酯
|
NZ518726A
(en)
|
2001-05-09 |
2004-06-25 |
Warner Lambert Co |
Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
|
AU2002310441A1
(en)
*
|
2001-06-14 |
2003-01-02 |
The Regents Of The University Of California |
A novel signaling pathway for the production of inflammatory pain and neuropathy
|
WO2003062191A1
(en)
|
2002-01-23 |
2003-07-31 |
Warner-Lambert Company Llc |
N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
|
DOP2003000556A
(es)
|
2002-01-23 |
2003-10-31 |
Warner Lambert Co |
Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
|
US7235537B2
(en)
*
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
HUE025767T2
(en)
|
2002-03-13 |
2016-05-30 |
Array Biopharma Inc |
N3-alkylated benzimidazole derivatives as MEK inhibitors
|
AU2003224052A1
(en)
*
|
2002-04-09 |
2003-10-20 |
Novartis Ag |
Compositions comprising mmp7 modulators for the treatment of chronic pain
|
MXPA05003431A
(es)
*
|
2002-11-15 |
2005-07-05 |
Warner Lambert Co |
Quimioterapia de combinacion.
|
US7378233B2
(en)
|
2003-04-12 |
2008-05-27 |
The Johns Hopkins University |
BRAF mutation T1796A in thyroid cancers
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
TW200520745A
(en)
*
|
2003-09-19 |
2005-07-01 |
Chugai Pharmaceutical Co Ltd |
Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
|
KR101013932B1
(ko)
*
|
2003-10-21 |
2011-02-14 |
워너-램버트 캄파니 엘엘씨 |
N-[(r)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태
|
AU2004293019B2
(en)
|
2003-11-19 |
2010-10-28 |
Array Biopharma Inc. |
Bicyclic inhibitors of MEK and methods of use thereof
|
US7732616B2
(en)
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
US7517994B2
(en)
*
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
EP1684694A2
(en)
|
2003-11-21 |
2006-08-02 |
Array Biopharma, Inc. |
Akt protein kinase inhibitors
|
UA89035C2
(ru)
|
2003-12-03 |
2009-12-25 |
Лео Фарма А/С |
Эфиры гидроксамовых кислот и их фармацевтическое применение
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
WO2005094830A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
US7378423B2
(en)
|
2004-06-11 |
2008-05-27 |
Japan Tobacco Inc. |
Pyrimidine compound and medical use thereof
|
CN101006086B
(zh)
|
2004-06-11 |
2010-09-29 |
日本烟草产业株式会社 |
用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
|
TWI361066B
(en)
|
2004-07-26 |
2012-04-01 |
Chugai Pharmaceutical Co Ltd |
5-substituted-2-phenylamino benzamides as mek inhibitors
|
US7732472B2
(en)
*
|
2004-08-18 |
2010-06-08 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
EP1802579B1
(en)
|
2004-10-20 |
2013-11-20 |
Merck Serono SA |
Derivatives of 3-arylaminopyridine
|
WO2006061712A2
(en)
*
|
2004-12-10 |
2006-06-15 |
Pfizer Inc. |
Use of mek inhibitors in treating abnormal cell growth
|
ES2405785T3
(es)
|
2005-05-18 |
2013-06-03 |
Array Biopharma Inc. |
Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
|
WO2006134469A1
(en)
*
|
2005-06-14 |
2006-12-21 |
Warner-Lambert Company Llc |
Methods of preparing mek inhibitor
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
WO2007042885A2
(en)
*
|
2005-10-07 |
2007-04-19 |
Pfizer Products Inc. |
Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2
|
NZ567140A
(en)
|
2005-10-07 |
2011-09-30 |
Exelixis Inc |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
JP5527972B2
(ja)
|
2005-11-11 |
2014-06-25 |
エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規のピリドピラジン及び前記ピリドピラジンをキナーゼのモジュレーターとして用いる使用
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
EP1790342A1
(de)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
EP2054418B1
(en)
|
2006-07-06 |
2011-11-09 |
Array Biopharma Inc. |
Dihydrothieno pyrimidines as akt protein kinase inhibitors
|
CA2656618C
(en)
|
2006-07-06 |
2014-08-26 |
Array Biopharma Inc. |
Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
ATE493418T1
(de)
|
2006-07-06 |
2011-01-15 |
Array Biopharma Inc |
Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
|
AU2007286808B2
(en)
*
|
2006-08-21 |
2012-12-06 |
Genentech, Inc. |
Aza-benzofuranyl compounds and methods of use
|
RU2444524C2
(ru)
*
|
2006-08-21 |
2012-03-10 |
Дженентек, Инк. |
Азабензотиофенильные соединения и способы применения
|
CN101583616B
(zh)
*
|
2006-08-21 |
2012-05-30 |
健泰科生物技术公司 |
氮杂苯并噻吩基化合物及使用方法
|
BRPI0714629A2
(pt)
*
|
2006-08-21 |
2013-05-07 |
Genentech Inc |
composto, composiÇço farmacÊutica, mÉtodo para inibir o crescimento celular, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para trataruma doenÇa auto-imune, lesço àsseo destrutiva, distérbios proliferativos, doenÇas infecciosas, doenÇas virais, doenÇas fibràticas ou doenÇas neurodegenerativas
|
MX2009004269A
(es)
|
2006-10-23 |
2009-08-12 |
Takeda Pharmaceutical |
Inhibidores de cinasa mapk/erk.
|
CN101605540A
(zh)
|
2006-12-14 |
2009-12-16 |
埃克塞利希斯股份有限公司 |
使用mek抑制剂的方法
|
JO2985B1
(ar)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
JP5580735B2
(ja)
|
2007-06-12 |
2014-08-27 |
ジェネンテック, インコーポレイテッド |
N−置換アザインドール類及び使用方法
|
CN101801955B
(zh)
|
2007-07-05 |
2013-05-08 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
JP5542282B2
(ja)
|
2007-07-05 |
2014-07-09 |
アレイ バイオファーマ、インコーポレイテッド |
Aktプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
PL2690101T3
(pl)
|
2007-12-19 |
2015-12-31 |
Genentech Inc |
5-anilinoimidazopirydyny i sposoby zastosowania
|
DK2231662T3
(da)
|
2007-12-19 |
2011-08-29 |
Genentech Inc |
8-Anilinoimidazopyridiner og deres anvendelse som anticancer- og/eller antiinflammatoriske midler
|
CN101896469A
(zh)
|
2007-12-20 |
2010-11-24 |
霍夫曼-拉罗奇有限公司 |
作为mek激酶抑制剂的取代的乙内酰脲类化合物
|
ES2387707T3
(es)
*
|
2007-12-21 |
2012-09-28 |
Genentech, Inc. |
Azaindolizinas y procedimientos de uso
|
AU2009204025B2
(en)
|
2008-01-09 |
2014-02-20 |
Array Biopharma Inc. |
Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
AU2009204019B2
(en)
|
2008-01-09 |
2014-02-20 |
Array Biopharma Inc. |
Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
|
EP2240494B1
(en)
|
2008-01-21 |
2016-03-30 |
UCB Biopharma SPRL |
Thieno-pyridine derivatives as mek inhibitors
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
AU2009266956B2
(en)
|
2008-07-01 |
2014-03-20 |
Genentech, Inc. |
Bicyclic heterocycles as MEK kinase inhibitors
|
CN102137843A
(zh)
|
2008-07-01 |
2011-07-27 |
健泰科生物技术公司 |
作为mek激酶抑制剂的异吲哚酮衍生物及其使用方法
|
BRPI0916566B8
(pt)
|
2008-08-04 |
2021-05-25 |
Merck Patent Ges Mit Beschraenkter Haftung |
isonicotinamida fenilamina, seu uso, composição farmacêutica, e kit
|
US8350026B2
(en)
|
2008-08-27 |
2013-01-08 |
Leo Pharma A/S |
VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof
|
US8278105B2
(en)
*
|
2008-09-09 |
2012-10-02 |
University Of Southern California |
Induction, propagation and isolation of liver progenitor cells
|
ES2399384T3
(es)
|
2008-11-10 |
2013-04-01 |
Bayer Schering Pharma Ag |
Sulfonamido fenoxibenzamidas sustituidas
|
JP5651125B2
(ja)
|
2008-12-10 |
2015-01-07 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Mek阻害剤に対する耐性を付与するmek突然変異
|
SG178986A1
(en)
|
2009-09-08 |
2012-04-27 |
Hoffmann La Roche |
4-substituted pyridin-3-yl-carboxamide compounds and methods of use
|
WO2011038082A1
(en)
*
|
2009-09-23 |
2011-03-31 |
Glaxosmithkline Llc |
Combination
|
US20110086837A1
(en)
*
|
2009-10-12 |
2011-04-14 |
Genentech, Inc. |
Combinations of a pi3k inhibitor and a mek inhibitor
|
WO2011047788A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
EP2491014A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted halophenoxybenzamide derivatives
|
EP2491016A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
CN102791715B
(zh)
|
2009-12-31 |
2016-04-27 |
卡洛斯三世国家癌症研究中心基金会 |
用作激酶抑制剂的三环化合物
|
US9073927B2
(en)
|
2010-01-22 |
2015-07-07 |
Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii |
Inhibitors of PI3 kinase
|
US20130065883A1
(en)
|
2010-02-18 |
2013-03-14 |
Centro Nacional de Investigaceiones Oncologicas (CNIO) |
Triazolo [4, 5- B] Pyridin Derivatives
|
BR112012021411A2
(pt)
|
2010-02-25 |
2017-04-18 |
Dana Farber Cancer Inst Inc |
mutações braf que conferem resistência a inibidores braf.
|
ES2714875T3
(es)
|
2010-03-09 |
2019-05-30 |
Dana Farber Cancer Inst Inc |
Métodos de diagnóstico y tratamiento del cáncer en pacientes que presentan o desarrollan resistencia a una primera terapia del cáncer
|
WO2011121317A1
(en)
|
2010-04-01 |
2011-10-06 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
WO2012052745A1
(en)
|
2010-10-21 |
2012-04-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Combinations of pi3k inhibitors with a second anti -tumor agent
|
EP2632899A1
(en)
|
2010-10-29 |
2013-09-04 |
Bayer Intellectual Property GmbH |
Substituted phenoxypyridines
|
CN102020651B
(zh)
|
2010-11-02 |
2012-07-18 |
北京赛林泰医药技术有限公司 |
6-芳基氨基吡啶酮甲酰胺mek抑制剂
|
CA2822638C
(en)
|
2010-12-22 |
2021-02-16 |
Fate Therapeutics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
CN102649773A
(zh)
*
|
2011-02-23 |
2012-08-29 |
苏州波锐生物医药科技有限公司 |
氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
|
MX2013011333A
(es)
|
2011-04-01 |
2014-04-16 |
Genentech Inc |
Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
|
RU2631240C2
(ru)
|
2011-04-01 |
2017-09-20 |
Дженентек, Инк. |
Комбинации соединений-ингибиторов акт и абиратерона, и способы применения
|
CN103748099B
(zh)
|
2011-05-19 |
2016-08-17 |
卡洛斯三世国家癌症研究中心基金会 |
作为蛋白激酶抑制剂的大环化合物
|
EP2524918A1
(en)
|
2011-05-19 |
2012-11-21 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Imidazopyrazines derivates as kinase inhibitors
|
US20140228418A1
(en)
*
|
2011-05-23 |
2014-08-14 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mek inhibitors
|
WO2012160130A1
(en)
|
2011-05-25 |
2012-11-29 |
Universite Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
WO2013005041A1
(en)
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Tricyclic heterocyclic compounds as kinase inhibitors
|
WO2013005057A1
(en)
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
New compounds
|
WO2013004984A1
(en)
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Tricyclic compounds for use as kinase inhibitors
|
PT3409278T
(pt)
|
2011-07-21 |
2020-12-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de proteína cinase heterocíclicos
|
CN103764144B
(zh)
|
2011-08-31 |
2016-07-20 |
诺华股份有限公司 |
Pi3k抑制剂与mek抑制剂的协同组合
|
EP2773345A1
(en)
|
2011-11-02 |
2014-09-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
EP2776025A1
(en)
|
2011-11-02 |
2014-09-17 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with platinum-containing agents
|
JP2014533299A
(ja)
|
2011-11-14 |
2014-12-11 |
シンタ ファーマシューティカルズ コーポレーション |
Braf阻害剤とhsp90阻害剤の組合せ療法
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
CN102532089B
(zh)
*
|
2011-12-22 |
2014-05-14 |
凯莱英医药集团(天津)股份有限公司 |
一种制备手性甘油醇缩丙酮的方法
|
BR112014016870A2
(pt)
|
2012-01-09 |
2017-06-27 |
Huesken Dieter |
composições orgânicas para tratar doenças relacionadas com beta-catenina
|
CN103204827B
(zh)
|
2012-01-17 |
2014-12-03 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
|
WO2013169858A1
(en)
|
2012-05-08 |
2013-11-14 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
JP2015527874A
(ja)
|
2012-05-31 |
2015-09-24 |
バイエル ファーマ アクチエンゲゼルシャフト |
肝細胞癌(hcc)患者の治療の有効な応答を決定するためのバイオマーカー
|
SI2909188T1
(en)
|
2012-10-12 |
2018-07-31 |
Exelixis, Inc. |
A novel process for the manufacture of compounds for use in the treatment of cancer
|
US9394257B2
(en)
|
2012-10-16 |
2016-07-19 |
Tolero Pharmaceuticals, Inc. |
PKM2 modulators and methods for their use
|
CA2889381C
(en)
*
|
2012-11-15 |
2023-01-03 |
Duquesne University Of The Holy Ghost |
Carboxylic acid ester prodrug inhibitors of mek
|
DK2925366T3
(en)
|
2012-11-29 |
2018-06-06 |
Novartis Ag |
PHARMACEUTICAL COMBINATIONS
|
EP2752191A1
(en)
|
2013-01-07 |
2014-07-09 |
Sanofi |
Compositions and methods using hdm2 antagonist and mek inhibitor
|
EP2963114B1
(en)
|
2013-02-27 |
2018-12-12 |
Daiichi Sankyo Company, Limited |
Method for predicting responsiveness to compound inhibiting mapk signal transduction pathway
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
JP6315848B2
(ja)
*
|
2013-03-13 |
2018-04-25 |
ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン |
Mek/pi3k二重阻害剤および該阻害剤を使用する治療方法
|
ES2969245T3
(es)
|
2013-03-14 |
2024-05-17 |
Msd Int Gmbh |
Formas cristalinas y métodos para preparar inhibidores de SGLT2
|
CA2905993C
(en)
|
2013-03-14 |
2022-12-06 |
Tolero Pharmaceuticals, Inc. |
Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
|
EP3514178A1
(en)
|
2013-03-15 |
2019-07-24 |
Novartis AG |
Antibody drug conjugates
|
WO2015038704A1
(en)
|
2013-09-11 |
2015-03-19 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Compositions for preparing cardiomyocytes
|
EP3043790B1
(en)
*
|
2013-09-11 |
2021-05-26 |
The Administrators of the Tulane Educational Fund |
Novel anthranilic amides and the use thereof
|
SG10201902429PA
(en)
|
2013-11-11 |
2019-04-29 |
Amgen Inc |
Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
|
CN104788365B
(zh)
*
|
2014-01-16 |
2018-08-10 |
上海艾力斯医药科技有限公司 |
异烟酰胺衍生物、其制备方法及应用
|
AU2015227184B2
(en)
|
2014-03-04 |
2021-05-20 |
Fate Therapeutics, Inc. |
Improved reprogramming methods and cell culture platforms
|
US10023879B2
(en)
|
2014-06-04 |
2018-07-17 |
Fate Therapeutics, Inc. |
Minimal volume reprogramming of mononuclear cells
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
KR20170040249A
(ko)
|
2014-08-12 |
2017-04-12 |
노파르티스 아게 |
항-cdh6 항체 약물 접합체
|
CN105384754B
(zh)
*
|
2014-09-02 |
2018-04-20 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
CN107206071A
(zh)
|
2014-09-13 |
2017-09-26 |
诺华股份有限公司 |
Alk抑制剂的联合疗法
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
AU2015328411C1
(en)
|
2014-10-06 |
2022-03-03 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
JP6831783B2
(ja)
|
2014-11-14 |
2021-02-17 |
ノバルティス アーゲー |
抗体薬物コンジュゲート
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
SG11201703880VA
(en)
|
2014-12-23 |
2017-07-28 |
Novartis Ag |
Triazolopyrimidine compounds and uses thereof
|
JP6800859B2
(ja)
|
2015-01-26 |
2020-12-16 |
フェイト セラピューティクス,インコーポレイテッド |
造血細胞分化を誘導するための方法および組成物
|
CA2976766A1
(en)
|
2015-03-25 |
2016-09-29 |
Novartis Ag |
Formylated n-heterocyclic derivatives as fgfr4 inhibitors
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
CN104906081A
(zh)
*
|
2015-05-25 |
2015-09-16 |
上海中医药大学附属曙光医院 |
一种化合物在制备治疗骨关节炎药物中的应用
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
EP3340989B1
(en)
|
2015-08-28 |
2023-08-16 |
Novartis AG |
Mdm2 inhibitors and combinations thereof
|
JP7263005B2
(ja)
|
2015-10-16 |
2023-04-24 |
フェイト セラピューティクス,インコーポレイテッド |
基底状態の多能性の誘導及び維持に関するプラットフォーム
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
PT3371314T
(pt)
|
2015-11-04 |
2023-08-31 |
Fate Therapeutics Inc |
Modificação genómica de células pluripotentes
|
AU2016348342B2
(en)
|
2015-11-04 |
2023-07-06 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
CN105646438A
(zh)
*
|
2015-12-22 |
2016-06-08 |
天津大学 |
一种缩酮类糖醇基小分子凝胶因子及其制备方法和应用
|
US11413309B2
(en)
|
2016-01-20 |
2022-08-16 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
KR20180096707A
(ko)
|
2016-01-20 |
2018-08-29 |
페이트 세러퓨틱스, 인코포레이티드 |
입양 면역요법에서 면역 세포 조절을 위한 조성물 및 방법
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
KR20180118719A
(ko)
|
2016-03-04 |
2018-10-31 |
다이호야쿠힌고교 가부시키가이샤 |
악성 종양 치료용 제제 및 조성물
|
WO2017221092A1
(en)
|
2016-06-20 |
2017-12-28 |
Novartis Ag |
Triazolopyridine compounds and uses thereof
|
IL263429B
(en)
|
2016-06-20 |
2022-08-01 |
Novartis Ag |
Crystalline forms of a triazolopyrimidine compound
|
WO2017221100A1
(en)
|
2016-06-20 |
2017-12-28 |
Novartis Ag |
Imidazopyrimidine compounds useful for the treatment of cancer
|
WO2018009638A1
(en)
|
2016-07-06 |
2018-01-11 |
The Regents Of The University Of Michigan |
MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME
|
AU2017329090B9
(en)
|
2016-09-19 |
2019-09-05 |
Novartis Ag |
Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
|
WO2018092064A1
(en)
|
2016-11-18 |
2018-05-24 |
Novartis Ag |
Combinations of mdm2 inhibitors and bcl-xl inhibitors
|
WO2018106595A1
(en)
|
2016-12-05 |
2018-06-14 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
WO2018146253A1
(en)
|
2017-02-10 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
WO2018163051A1
(en)
|
2017-03-06 |
2018-09-13 |
Novartis Ag |
Methods of treatment of cancer with reduced ubb expression
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
DK3618875T3
(da)
|
2017-05-02 |
2023-07-10 |
Novartis Ag |
Kombinationsterapi omfattende en raf-inhibitor og trametinib
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
MX2019014023A
(es)
|
2017-05-24 |
2020-02-17 |
Novartis Ag |
Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
DK3769765T3
(da)
|
2018-03-19 |
2024-05-13 |
Taiho Pharmaceutical Co Ltd |
Farmaceutisk sammensætning indeholdende natriumalkylsulfat
|
BR112020020246A8
(pt)
|
2018-04-05 |
2022-10-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de cinase axl e uso dos mesmos
|
EP3788038B1
(en)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
WO2020012334A1
(en)
|
2018-07-10 |
2020-01-16 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
DE202018006567U1
(de)
|
2018-07-25 |
2021-02-22 |
Advanced Accelerator Applications Sa |
Stabile, konzentrierte Radionuklidkomplexlösungen
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|
JP7328323B2
(ja)
|
2018-08-17 |
2023-08-16 |
ノバルティス アーゲー |
SMARCA2/BRM ATPase阻害剤としての尿素化合物及び組成物
|
JP7358484B2
(ja)
|
2018-09-25 |
2023-10-10 |
アドヴァンスド・アクセラレーター・アプリケーションズ・(イタリー)・エッセエッレエッレ |
併用療法
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
CA3123511A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
JP2022520361A
(ja)
|
2019-02-12 |
2022-03-30 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
複素環式タンパク質キナーゼ阻害剤を含む製剤
|
KR20210129672A
(ko)
|
2019-02-15 |
2021-10-28 |
노파르티스 아게 |
치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
CN113747895A
(zh)
|
2019-03-22 |
2021-12-03 |
大日本住友制药肿瘤公司 |
包含pkm2调节剂的组合物和用其治疗的方法
|
CN114144414A
(zh)
|
2019-05-21 |
2022-03-04 |
美国安进公司 |
固态形式
|
US11529350B2
(en)
|
2019-07-03 |
2022-12-20 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
EP4025215A1
(en)
|
2019-09-02 |
2022-07-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of pyrvinium for the treatment of a ras pathway mutated acute myeloid leukemia
|
JP2022550353A
(ja)
|
2019-09-26 |
2022-12-01 |
ノバルティス アーゲー |
アザキノリン化合物およびその使用
|
CN115175937A
(zh)
|
2019-12-20 |
2022-10-11 |
诺华股份有限公司 |
用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
|
TW202200146A
(zh)
|
2020-04-10 |
2022-01-01 |
日商大鵬藥品工業股份有限公司 |
使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法
|
IL298473A
(en)
|
2020-06-11 |
2023-01-01 |
Novartis Ag |
zbtb32 inhibitors and uses thereof
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
AR123185A1
(es)
|
2020-08-10 |
2022-11-09 |
Novartis Ag |
Compuestos y composiciones para inhibir ezh2
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
KR20230170644A
(ko)
|
2021-02-02 |
2023-12-19 |
르 라보레또레 쎄르비에르 |
선택적 bcl-xl protac 화합물 및 사용 방법
|
CA3207513A1
(en)
|
2021-02-17 |
2022-08-25 |
Kristin Patterson |
Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof
|
WO2022177556A1
(en)
|
2021-02-17 |
2022-08-25 |
Warner-Lambert Company Llc |
Compositions of essentially pure form iv of n-((r)-2,3- dihydroxypropoxy)-3,4-difluoro-2- (2-fluoro-4-iodophenylamino)- benzamide and uses thereof
|
US11084780B1
(en)
|
2021-02-17 |
2021-08-10 |
Springworks Therapeutics, Inc. |
Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
|
US11066358B1
(en)
|
2021-02-17 |
2021-07-20 |
Warner-Lambert Company Llc |
Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
|
US11571402B2
(en)
|
2021-02-17 |
2023-02-07 |
Springworks Therapeutics, Inc. |
Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
|
AU2021428601A1
(en)
|
2021-02-17 |
2023-09-28 |
Springworks Therapeutics, Inc. |
Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4- difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
|
WO2022195551A1
(en)
|
2021-03-18 |
2022-09-22 |
Novartis Ag |
Biomarkers for cancer and methods of use thereof
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
PE20240327A1
(es)
|
2021-04-13 |
2024-02-22 |
Nuvalent Inc |
Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
CN114524753B
(zh)
*
|
2022-02-24 |
2024-03-26 |
安徽大学 |
一种多取代异羟肟酸衍生物的合成方法
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
WO2023178266A2
(en)
|
2022-03-17 |
2023-09-21 |
SpringWorks Therapeutics Inc. |
Fluorinated phenylamino compounds and pharmaceutical compositions
|
WO2023209611A1
(en)
|
2022-04-26 |
2023-11-02 |
Beigene Switzerland Gmbh |
Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023223205A1
(en)
|
2022-05-17 |
2023-11-23 |
Teva Pharmaceuticals International Gmbh |
Solid state forms of mirdametinib and process for preparation thereof
|
WO2023225320A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
TW202404645A
(zh)
|
2022-05-20 |
2024-02-01 |
瑞士商諾華公司 |
Met bcl-xl抑制劑抗體-藥物結合物及其使用方法
|
WO2024023666A1
(en)
|
2022-07-26 |
2024-02-01 |
Novartis Ag |
Crystalline forms of an akr1c3 dependent kars inhibitor
|